(5E)-5-(5-bromo-2-oxo-1H-indol-3-ylidene)-2-sulfanylidene-1,3-thiazolidin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (5E)-5-(5-bromo-2-oxo-1H-indol-3-ylidene)-2-sulfanylidene-1,3-thiazolidin-4-one
• 化学式: C₁₁H₅BrN₂O₂S₂
• 分子量: 341.2
• InChiKey: FYYNFIZWOMBUTO-BQYQJAHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Compositions and methods for treating pulmonary hypertension
  申请人：Acceleron Pharma Inc.

  公开号：US10695405B2

  公开（公告）日：2020-06-30

  In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

  在某些方面，本公开涉及GDF/BMP拮抗剂和使用GDF/BMP拮抗剂治疗、预防或降低肺动脉高压（PH）进展率和/或严重程度的方法，特别是治疗、预防或降低一种或多种PH相关并发症的进展率和/或严重程度的方法。本公开还提供了使用GDF/BMP拮抗剂治疗、预防或降低各种病症（包括但不限于肺血管重塑、肺纤维化和右心室肥大）的进展速度和/或严重程度的方法。本公开进一步提供了使用 GDF/BMP 拮抗剂降低有需要的受试者右心室收缩压的方法。
• ALK4.ActRIIB heteromultimers
  申请人：Acceleron Pharma Inc.

  公开号：US10934532B2

  公开（公告）日：2021-03-02

  In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.

  在某些方面，本公开提供了包含 ALK4 受体胞外结构域和 ActRIIB 胞外结构域的可溶性异构多肽复合物。在某些方面，这种可溶性 ALK4:ActRIIB 复合物可用于调节（促进或抑制）组织或细胞的生长，例如包括肌肉、骨骼、软骨、脂肪、神经组织、肿瘤和/或癌细胞。在某些方面，此类 ALK4:ActRIIB 复合物可用于改善肌肉形成、骨骼形成、代谢参数以及与这些组织、细胞网络、肾脏和内分泌系统相关的疾病。
• COMPOSITIONS COMPRISING ACTRIIA POLYPEPTIDES FOR USE IN TREATING PULMONARY HYPERTENSION
  申请人：Acceleron Pharma Inc.

  公开号：EP3496739B1

  公开（公告）日：2021-04-28
• COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION
  申请人：Acceleron Pharma Inc.

  公开号：EP4081240A1

  公开（公告）日：2022-11-02
• ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF
  申请人：Acceleron Pharma Inc.

  公开号：US20180163187A1

  公开（公告）日：2018-06-14

  In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.